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Abstract  
Puberty is the period during which we attain adult secondary sexual characteristics and 
reproductive capability. Its onset depends upon re-activation of pulsative gonadotrophin 
releasing hormone (GnRH), secretion from its relative quiescence during childhood, on the 
background of intact potential for pituitary-gonadal function.  This review is intended to 
highlight those current practices in diagnosis and management that are evidence-based and 
those that are not; to help clinicians deal with areas of uncertainty with reference to physiologic 
first principles and to by sign-posting relevant data arising from other patient groups with 
shared issues; to illustrate how recent scientific advances are (or should be) altering clinician 
perceptions of pubertal delay, and finally,  to emphasis that the management of men and women 
presenting in advanced adult life with absent puberty cannot simply be extrapolated from 
paediatric practice.   
There is a broad spectrum of pubertal timing that varies among different populations, separated 
in time and space.  Delayed puberty usually represents an extreme of the normal, a 
developmental pattern referred to as constitutional delay of growth and puberty (CDGP), but 
organic defects of the hypothalamo-pituitary-gonadal axis predisposing to hypogonadism may 
not always be initially distinguishable from it.  CDGP and organic hypogonadism are both 
significantly more common in boys than girls.    Moreover, around 1/3 of adults with organic 
hypogonadotropic hypogonadism had evidence of partial puberty at presentation and, 
confusingly, some 5-10% of these subsequently may exhibit recovery of endogenous 
gonadotropin secretion, including men with Kallmann syndrome 1, 2.  However, the distinction is 
crucial as expectative (“watch-and-wait”) management is inappropriate in the context of 
hypogonadism.  The probability of pubertal delay being caused by organic hypogonadism rises 
exponentially both with increasing age at presentation and the presence of associated “red flag” 
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clinical features.  These “red flags” comprise findings indicating lack of prior “mini-puberty” 
(such as cryptorchidism, or micropenis), or the presence of non-reproductive congenital defects 
known to be associated with specific hypogonadal syndromes.  eg. anosmia, deafness, mirror 
movements, renal agenesis, dental/digital anomalies, clefting, or coloboma would be compatible 
with Kallmann (or, perhaps CHARGE) syndrome.  
In children, interventions (whether in the form or treatment, or simple reassurance) have been 
historically directed at maximising height potential and minimising psychosocial morbidity, 
though issues of future fertility and bone density potential are now increasingly “in the mix”.  
Apubertal adults almost invariably harbour organic hypogonadism, requiring sensitive 
acknowledgement of underlying personal issues and the timely introduction of sex hormone 
replacement therapy at more physiological doses.  
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Puberty is a period during which children attain adult secondary sexual characteristics and 
reproductive capability. The onset of puberty requires an intact hypothalamic-pituitary-gonadal 
(HPG) axis. Re-activation of the secretion of gonadotrophin releasing hormone (GnRH) from its 
stage of childhood quiescence stimulates luteinizing hormone (LH) and follicle stimulating 
hormone (FSH) secretion, which in turn activates the production of gonadal sex steroids.  
The first external sign of puberty in girls is usually the initiation of breast development, 
designated as change from Tanner stage B1 to B2 (B2; also called breast budding) and, in boys, 
change from Tanner's genital stage G1 to G2 including enlargement of the testes (i.e. achievement 
of volume greater than 3 ml or testicular length greater than or equal to 25 mm) 3-6.  
Development of pubic hair is usually not regarded as a marker for pubertal onset because 
pubarche may result from maturation of the adrenal glands (adrenarche) and onset of pubic hair 
can thus be independent of HPG axis activation.  
There are clear differences in pubertal timing among ethnic groups, but in most populations the 
average ages at attainment of the first signs of puberty are around 10 for girls and 12 in boys 7, 8.  
Puberty is delayed if there is no breast development by 13 years in girls or absence of testicular 
enlargement by 14 years in boys 6. Because of the secular change towards earlier onset of 
puberty in US 9, 10 and some other countries 7, 8 different age limits may be more appropriate in 
some ethnic groups. Even the latest developing girls seem to start their puberty one year earlier 
than two decades ago 7, 8. 
 
Evaluation of delayed puberty 
Constitutional delay of growth and puberty (CDGP) represents the commonest cause of delayed 
puberty in both sexes.  At least 30% of girls and up to 65% of boys and with delayed puberty 
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have CDGP 11.  Autosomal dominant mode of inheritance (with or without complete penetrance) 
is the commonest inheritance pattern and CDGP can affect both boys and girls 12.  Although CDGP 
does seem to be more frequent than might be expected among first degree relatives of probands 
with hypogonadotropic hypogonadism, the genetic basis of this observation remains elusive.  
Fifty to 75% of subjects with CDGP have a family history of delayed puberty.  As much as 80% of 
all variation in the timing of puberty is due to genetic factors 13, 14.  
CDGP can be considered an extreme of the normal spectrum of pubertal timing., but can be 
diagnosed only after exclusion of other underlying conditions.  The differential diagnosis of CDGP 
is divided into 3 main categories6, 11 -hypergonadotropic hypogonadism (characterized by 
elevated gonadotrophin levels due to lack of negative feedback from the gonads); permanent 
hypogonadotropic hypogonadism (characterized by low LH and FSH levels due to organic 
hypothalamic or pituitary disorders); and transient (or functional) hypogonadotropic 
hypogonadism, where pubertal delay is due to maturational delay in the HPG axis secondary to 
an underlying non-reproductive condition.  
One of the most difficult distinctions is that between CDGP and congenital IHH in teenage years. 
Subjects with CDGP are typically short, because their skeletal maturation is delayed and their 
height is compatible with the bone age.  In about half of adolescents with CDGP, linear growth has 
already begun to faltering in the years before the expected onset of puberty, and it has been 
shown that these children with poor growth in childhood do not fully exploit their genetic height 
potential and will ultimately have adult height significantly below their mid-parental target 
height 15.  By contrast, patients with congenital IHH have steady linear growth during childhood 
and only become short for their age with absence of the pubertal growth spurt.  In a typical case, 
the diagnosis of congenital IHH is made during the second or third decade of life.  Common 
presenting signs are delayed onset of puberty, primary amenorrhea, poorly developed secondary 
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sexual characteristics, eunuchoid body proportions, or infertility, though the diagnosis can 
sometimes be suspected before the age of pubertal onset (indeed, in the first six months of life it 
can actually be confirmed on the basis of low testosterone and gonadotropin levels).  For the 
differential diagnosis of the two conditions a variety of physiological and stimulation tests have 
been proposed, such as assessment of LH pulsatility by frequent sampling 16, prolactin response 
to various provocations 17,  gonadotrophin response to GnRH 18, testosterone response to hCG 19-
21 and first morning-voided urine FSH and LH 22.  Most recently, a single measurement of inhibinB 
level has been shown to discriminate IHH from CDGP with specificity of 100% at inhibinB 
concentration of 35 pg/mL in prepubertal boys 23.  However, the presence/absence of “red flag” 
features remains the strongest differentiator.  
In adults, the diagnostic value of the GnRH test is limited 24 and assessment of baseline 
gonadotrophin levels is usually sufficient.  Similarly, other hormones of the pituitary should be 
first evaluated by basal hormonal levels (measured by ultrasensitive assays), with provocation 
tests reserved for situations in which the basal hormone measurements are insufficiently 
informative, or in cases there is strong clinical evidence of a multiple pituitary hormone 
deficiency.  
Anosmia can often be diagnosed by simply asking the patient, but only semi-quantitative 
olfactometry (e.g. UPSIT) 25 can reliably distinguish between normal or partially-defective 
olfaction.  Accurate olfactory phenotyping can support more directed genetic testing 26.  MRI of 
the olfactory tract (especially T2-weighted corinal views) can readily demonstrate hypoplastic or 
absent olfactory bulbs, which are pathognomonic of Kallmann syndrome.  MRI should also be 
used in suspicion of pituitary and/or hypothalamic tumors, in patients with persistent 
hyperprolactinemia, multiple pituitary hormone deficiency, or neurological signs of a tumour 
clinical (visual field defects,  headache).  However, according to a recent clinical practice 
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guideline, the cost-effectiveness of MRI scan to exclude pituitary and/or hypothalamic tumors 
has not been established 27.  In contrast, for suspected functional causes of HH, MRI is seldom 
indicated.  We also recommend assessment of bone mineral density of the lumbar spine, femoral 
neck, and hip at the initial diagnosis of HH and after 1 to 3 years of sex steroid therapy in 
hypogonadal patients (though if resources limited the number of scans, then obviously the key 
time would be after the first few years of treatment). 
At present, several things limit our ability to integrate genetic mutational analysis into everyday 
clinical practice.  First, our knowledge of the spectrum of genes involved is incomplete.  Second, 
so is our knowledge of adult phenotypes associated even with sequence variants of known genes.  
Third, the timelines for turnaround of genetic data from research labs are generally longer than 
clinicians have available to make decisions.  However, there are circumstances where clinical 
genetics can play a key role, such as where there is already a known high-penetrance genetic 
variant (eg. KAL1, FGFR1) segregating within a given kindred. 
Another diagnostic challenge is with slim gonadotropin-deficient women is that between organic 
disease and functional hypothalamic amenorrhoea (HA), relating to bioenergetic stress and/or 
occult underlying non-gonadal disease.  Indeed, with particularly severe stress, gonadotropin 
levels can even become suppressed in women with primary ovarian failure.  Pragmatically, 
however, the endocrine aspects to treatment are the same (oestrogen for induction/maintenance 
of post-adrenarchial secondary sexual characteristics and bone health; ovulation-induction with 
gonadotropins for infertility).  Moreover, there is now known to be genetic overlap between 
organic and functional gonadotropin deficiency syndromes, such that HA is now more usefully 
considered as resulting from genetic-environmental interactions 28. 
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Considerations in different diagnostic groups 
Induction of puberty is commonly considered for adolescents who either have delayed puberty, 
or have been diagnosed with hypogonadism.  Appropriate treatment modalities vary by the 
diagnosis.  Commonest causes of hypogonadism causing delayed puberty are listed in Table 1.  
For men and women presenting with absent or partial puberty and biochemical 
hypogonadotropic hypogonadism beyond the teenage years, the diagnostics and treatment aims 
are straightforward.  CDGP is no longer a likely diagnosis and, as these individuals have generally 
already attained normal adult stature, this (a) makes it improbable that they should harbour 
broader hypopituitarism beyond isolated gonadotropin deficiency (though serum screening for 
hyperprolactinaemia, iron overload and, possibly, coeliac disease is essential) and (b) removes 
any potential therapeutic conflicts between the goals of maximising final height and promptness 
of pubertal-induction.  Sex hormone replacement in hitherto apubertal adults can result in 
dramatic improvements in bone density, even when this treatment has only been initiated in 
middle age.   
The reasons for highly-delayed presentations beyond the teenage years in some patients with  
IHH/KS  have not been subject to any formal analysis, but recurrent themes emerge from both 
physician personal experience, and from patient experiences shared at focus groups and/or in 
online electronic traffic on the various support group-hosted sites.  These include general 
shyness (of patient and/or parents), constitutional reluctance or financial constraints inhibiting 
engagement with healthcare systems, strongly-held beliefs expressed by friends, family or 
physicians that “everything will be alright in the end” and, frankly, overt errors of omission or 
procrastination made by physicians they encountered in earlier life.  The association of pubertal 
delay with a history of any reproductive, or non-reproductive defect associated with “red flag 
markers” of permanent hypogonadism (micropenis, cryptorchidism, anosmia, deafness, clefting, 
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etc) should be a diagnostic “game-changer”, but all too often isn’t 29.  Some patients have pointed 
to intensive and, perhaps, over-enthusiastic investigation at their initial presentation as having 
induced them to miss follow-up visits and disengage with Endocrine follow-up for many years 
thereafter.  Patients from cultures favouring arranged-marriage and/or “modesty” in clothing-
coverage can also occasionally remain undiagnosed until the outcome of infertility investigations.  
The case histories contained in the online supplementary data from Santhakumar, et al. 2013 
illustrate most of these issues 37.  
In CDGP, where pubertal delay is transient, the patient should make the decision regarding 
whether the treatment is initiated, but if there are “red flag” markers of permanent 
hypogonadism there is no reason to defer treatment; the goal of such therapy is to accelerate 
growth and/or to induce secondary sexual characteristics and, potentially, to alleviate 
psychosocial difficulties. Late puberty can affect psychosocial well-being and, as late developing 
adolescent are often short compared with their peers, patients and families are often concerned 
that delayed puberty may also affect adult stature.  Many adolescents present with delayed 
puberty combined with relative familial short stature, compounding these concerns and leading 
to more subspecialty referrals than would either condition alone; however adult height only 
slightly below the genetic height potential (target height) is usually reached 30.  If stature is not a 
major concern, reassurance with accurate adult height prediction is frequently sufficient, 
especially if puberty has already started.  Hormonal therapy can be beneficial, especially for those 
who have decreased self-esteem, if there is clear anxiety about growth rate and/or delayed 
pubertal characteristics, or if there are psychosocial difficulties that may derive from negative 
interactions with peers. 31-34 
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If endogenous gonadotropin-dependent puberty has not started after one year of treatment, then 
permanent hypogonadotropic hypogonadism and other diagnoses should be reconsidered and an 
MRI of the brain is indicated.  
For the treatment of ovarian failure in girls with Turner syndrome there is significant uncertainty 
about the appropriate timing and dosage for oestrogen-replacement therapy 35-37.  Elevated 
gonadotrophin levels and slow skeletal maturation suggest that oestrogen deficiency in Turner 
girls begins already in infancy 38, 39.  Oestrogen may also have positive behavioural and 
neurocognitive effects in the developing brain 40, 41.  Despite this evidence, until recently a 
common clinical practice has been to postpone oestrogen -replacement therapy until the mid-
teens.  This practise was based on the widely-held view that too-early onset of oestrogen therapy 
might reduce adult height by accelerating epiphyseal fusion 42. This view has been revised by 
studies showing that postponing oestrogen replacement in adolescent girls with Turner 
syndrome may compromise self-esteem and social adjustment and does not provide beneficial 
effect on height adult height 36. Indeed, recent data from a placebo-controlled study suggest that 
combining ultra-low-doses of ethinyl oestradiol (as low as 25 ng per kilogram daily for children 
from 5.0 to 8.0 years of age; 50 ng per kilogram daily for those aged 8.0 to 12.0 years of age) with 
growth hormone, may improve growth and provide other potential benefits (ClinicalTrials.gov 
number, NCT00001221) 43.  Obviously, this study would bear repeating using tiny doses of 17b 
oestradiol, given the illogicality inherent in using ethinyl oestradiol as “estrogen replacement” for 
patients on growth hormone (q.v.).  Moreover, there are also data linking a history of late 
introduction of oestrogen therapy with incomplete uterine maturation in adult Turner women, 
which could impact adversely on egg-donation outcomes 44. 
How to Treat  
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CDGP:  The options for management of CDGP include expectant observation or therapy with low 
dose testosterone (in boys) or oestrogen (in girls) (Table 2).  Numerous studies of treatment of 
CDGP in boys have been reported.  These are largely observational and some randomized 
controlled trials (performed with small numbers of subjects) which involve low doses of 
androgens given in short courses 32, 34, 45.  Such therapy expedites growth but does not advance 
bone age over calendar age, advances sexual maturation and often improves psychosocial well-
being.  For girls, similar outcomes are likely although published data are scarce.  For girls therapy 
is initiated with appropriately low doses of oestrogen (Table 2).  CDGP is an overlapping 
condition with idiopathic short stature (ISS) and, for a subset of patients, short stature can be 
more concerning than delayed puberty.  Although the US FDA has approved GH for the treatment 
of ISS and height SDS < 2.25 for age, this therapy increase adult height only modestly in CDGP and 
its use is not recommended.  
In short boys with CDGP another potential therapeutic approach is inhibition of oestrogen 
biosynthesis with aromatase inhibitors,46, 47.  Aromatase inhibitors (AIs) inhibit conversion of 
androgens to oestrogens; because oestrogen is the predominant hormone needed for epiphyseal 
closure, AIs could prolong growth in height and thus potentially increase final adult height.  In 
boys with short stature and/or delayed puberty, AIs are reported to delay bone maturation and 
appear to increase adult height in controlled trials 46, 47.  However, the treatment efficacy in cm’s 
gained as well as the optimal dose, timing, and duration of treatment remain uncertain.  In 
particular, typical doses used for the treatment of ER+ breast cancers are almost certainly far too 
high for this putative indication.  Moreover, potential adverse effects, especially impaired 
trabecular bone development and vertebral body deformities observed in boys with ISS treated 
with letrozole 48 must also be considered.  Pending the outcome of ongoing clinical trials of these 
agents, therapy should be with testosterone alone unless stature is an overwhelming concern.  
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We do not use GH or anabolic steroids, and believe that aromatase inhibitors are most 
appropriately used within clinical trials for the present time. 
For boys with CDGP who elect to be treated, we initiate supplementation with 50 mg 
testosterone ester IM each month for 3-6 months, which can be repeated for another 3-6 months 
with dose escalation (Table 2).   
For girls we prefer oral or transdermal 17b-oestradiol for several reasons.  First, it is a 
precautionary principle to replace any given endocrine deficiency with the bioidentical hormone, 
whenever practical.  Second, data from hypopituitary females, receiving combined oestrogen and 
GH, treatment indicate a markedly greater impairment of GH-mediated IGF1 synthesis with 
ethinyloestradiol than with 17b-oestradiol 49, with a smaller inhibitory effect observed  by taking 
17b-oestradiol transdermally versus orally 50. Finally, data from UK & Dutch registries of trans-
women (male-to-female trans-sexuals) have highlighted a much greater risk of venous and/or 
arterial thrombosis with ethinyloestradiol and conjugated equine estrogens than with 17b-
oestradiol 51-53.  Given that linear growth is an intrinsic concern in CDGP, it seems both unwise 
and unnecessary (despite longstanding habit and custom) to expose young girls to a synthetic 
molecule, with demonstrably higher thrombosis-risk and the theoretical potential for growth 
impairment, when there is a better alternative.   
When deciding whether to use oral, or transdermal 17b oestradiol, the following factors should 
be considered.  First, beyond the potential for better GH-mediated IGF1 synthesis, data from 
postmenopausal women suggest other advantages of the transdermal route in avoiding hepatic 
first-pass metabolism, both in respect of potentially lower thrombogenicity 54 and more neutral 
effect on lipids, with oral oestrogens tending to lower LDL-cholesterol and raise triglycerides 55   
Second, it is usually easier to administer tiny doses of 17b-oestradiol by cutting up a matrix 
patch, or using a metered-dose gel dispenser, than it is to split tablets.  However, patient 
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acceptability and product-preference is crucial and, before getting too fixated on the minutiae of 
dosimetry, the huge individual variability in drug absorption needs to be recognised.  Roughly-
speaking, similar plasma levels are achieved using 2mg daily oral 17b-oestradiol, 2mg daily gel 
and 100mcg patch, but with up to 10-fold differences in 17b-oestradiol levels between individual 
patients using the same preparation (eg. 50)  
Hypogonadotropic Hypogonadism: In boys and girls with HH, initial sex steroid therapy is the 
same as for CDGP (indeed the two diagnoses may not always be initially distinguishable), but 
doses are gradually increased to full adult replacement levels over approximately three years 
(Table 2).  Exogenous testosterone does not induce testicular growth or spermatogenesis in men 
with hypogonadotropic hypogonadism.  Equally, exogenous oestrogen does not induce ovulation 
(findings that clinch the diagnosis), and induction of fertility in both sexes requires treatment 
with either pulsatile GnRH 56-58 or exogenous gonadotrophins 58.  Fertility outcomes with each 
regimen are variable, with poorer responses in patients with signs of absent mini-puberty 
(prepubertal testes, cryptorchidism, and/or low IB) 57, 59.   
Induction of puberty adolescent males with either hCG monotherapy or with combinational 
therapy of hCG + rFSH may result in better testicular growth and improvement in potential 
fertility compared to treatment with testosterone therapy 60.  If the patient has spontaneous 
onset of pubertal development one can start with hCG monotherapy; FSH can be added in case 
azoospermia persists after 6-12 months of treatment. Early induction of spermatogenesis may 
increase sperm production capacity and reduce the time required for appearance of sperm once 
fertility is desired.  Monotherapy of hCG alone is at least theoretically less efficacious in the 
induction of spermatogenesis induction than combinational therapy of hCG + FSH 60, 61. 
The optimal regimen to maximize the potential for fertility in severe cases, i.e. those with 
testicular volume <4mL, is unknown.  FSH pre-treatment may plausibly maximize the Sertoli cell 
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population before exposure to hCG or GnRH-induced endogenous LH and thus has the potential 
to improve fertility outcomes 62.  In girls with HH, treatment with oestrogen needs to be 
combined with progestin for endometrial cycling. 
For older men and women presenting with IHH, pharmacologic treatment is potentially much 
simpler, though psychological support is a frequently-unmet need that is only partly 
compensated for by help available from patient support groups.  The only factors limiting the 
tempo and dosimetry of pubertal-induction in men are the absolute requirements to avoid 
erythrocytosis and psychological destabilisation related to a late coming-to-terms with issues of 
libido and sexuality.  Given that these patients delayed their presentations for so long, it may 
seem counterintuitive that they should wish to “get it all over with as soon and as simply as 
possible”, but that is a commonly-expressed wish, and they can easily become frustrated and 
disappointed with the apparent slowness of their progress on “paediatric” doses of testosterone.  
A regime comprising stepwise incremental doses of testosterone gel via calibrated dispenser 
would appear to offer the best possibility of achieving physiological simulation of male puberty.  
However, when offered the choice, our older apubertal men have almost universally chosen a less 
physiological, but for them much simpler regime, of 4-monthly intramuscular depot injections of 
Testosterone undecanoate 1g, leading to full pubertal development after around one year, 
without any apparent excursions of haematocrit, or reported psychological difficulties, or “drop-
outs” 63.  Given the lack of an observed “andropause” in normal men and the huge degree of 
overlap between the adverse consequences of untreated hypogonadism and those or normal 
male ageing (sarcopaenia, osteopaenia, anaemia, etc), there is no plausible upper age-limit 
beyond which pubertal-induction should not generally be undertaken.    
For older hypogonadal women, the factors limiting the tempo and dosimetry of oestrogen 
replacement are the need to optimise breast development and to minimise sensations of bloating 
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and/or breast discomfort that can arise on initial exposure.  These women may already have 
severe osteoporosis and/or sustained a low-trauma fracture, but we would encourage physicians 
not to reflexly initiate antiresorptive therapy with bisphosphonate right at the outset.  These 
agents lack an evidence base in women (and men) who are totally naïve to sex hormones and, 
moreover, also lack adequate safety and efficacy data much beyond five to ten years anyway.  So 
bisphosphonates are ideally kept in reserve for later life when discontinuation of oestrogen/ 
Progestogen replacement is being contemplated.   
Unlike the careful dose-titration typically performed for hypogonadal men, oestrogen/ 
Progestogen replacement therapy in adult women has traditionally been entirely empirical, 
based upon the capacity of a preparation to induce withdrawal bleeds (short-term signal), or to 
improve/maintain bone density on serial DEXA scanning (ultra-long-term signal).  This is 
another area where the optimal management of hypogonadal women might usefully be informed 
by patient registry data held in relation to trans-women, for whom therapy titrated to achieve 
serum oestradiol levels in the 300-400pmol/L range seems to give the best trade-off between 
benefits and risks 52.  In women with impaired bone density at baseline, it is logical to defer bone-
directed antiresorptive therapies at least until after maximum anabolic effect of oestrogen on 
bone has been achieved, as ascertained by serial DEXA scans.  There are no data to inform an 
evidence-based decision on when to stop sex hormone replacement in a hypogonadal woman.  
However, if bone density is an issue (which it usually is), then it is logical to continue 
replacement therapy at least until the upper end of the age range for normal age at menopause. 
Male Hypergonadotropic Hypogonadism: Klinefelter syndrome is by far the commonest (0.1-
0.2% birth prevalence) cause of hypergonadotrophic hypogonadism in males and comprises a 
wide spectrum of clinical and biochemical severity.  Nevertheless, as virtually all affected boys 
manage to initiate puberty, the clinical picture of partial puberty that may be evident in later life 
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may reflect secondary regression-effect, more than primary failure of attainment.  Only a 
minority of Klinefelter boys have come to the attention of an Endocrinologist by the end of their 
teenage years, but such patients present potentially difficult management decisions in terms of 
optimizing fertility outcomes.   
These have already been extensively reviewed elsewhere 64, 65 but in essence relate to the 
following issues.  First, although the techniques, success rates and general availability for 
testicular biopsy (or microdissection), sperm retrieval and sperm cryopreservation are 
continually advancing, this is counterbalanced by the rate of progressive seminiferous tubule 
degeneration occurring in the patients themselves.   Second, the most invasive (& successful) 
sperm retrieval techniques have the potential to cause the most  testicular damage and so would 
ideally be reserved for those men actively desiring fertility, in whom this could be combined with 
superovulation-induction, ICSI and embryo transfer into their partners.  Yet fertility is typically 
not at the forefront of the minds of Klinefelter adolescents, who are at the very peak of their 
fertility potential then.  Finally, it has been suggested that early exposure to exogenous 
testosterone may reduce success rates of sperm retrieval.  All these factors make for difficult 
conversations with vulnerable young men and their parents.   
Regarding the appropriate time to commence androgen replacement in men with Klinefelter 
syndrome, the key parameters are serum testosterone level, haematocrit, bone density, patient 
well-being and sexual function.  Even if these remain individually within the male reference rage, 
the accumulation of longitudinal data showing a significant rate of decline, indicates that the time 
has come to initiate treatment.   
Areas of Uncertainty and future research 
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Studies are needed to assess what impact sex steroid supplementation has on the psychosocial 
distress experienced by individuals with delayed puberty, whether this distress has long-term 
consequences.  It is not known whether pubertal delay adversely affects adult bone mass 66 and 
whether potentially compromised bone health is a reason to initiate sex-steroid replacement.  
Different oestrogen formulations, routes of administration (oral vs. transdermal) and dosing 
regimens should be studied in controlled trials to develop of optimal therapy for girls with 
delayed puberty.   
Other areas for further evaluation include defining the optimal therapy for males with severe 
hypogonadotophic hypogonadism, characterized by cryptorchidism, micropenis and lack of 
spontaneous increase in testicular size in puberty.  For instance, should male neonates with 
bilateral cryptorchidism and/or micropenis be screened for hypogonadotrophic hypogonadism, 
by checking testosterone and gonadotrophin levels between one week and 6 months after birth?  
With advances in our knowledge of the genetics of IHH, we are also likely to be getting an 
increasing number of putative diagnoses made in pre-adolescent age, either as a result of family 
history, or from recognition of IHH-associated clinical features (anosmia, history of 
cryptorchidism, etc).  Might their future fertility outcomes be enhanced by the earliest possible 
exposure to FSH, so as to “catch up” on the minipuberty that they never had?  
The minority of Turner girls who maintain normal ovarian function (evidenced by persistent 
menstrual cyclicity and normal levels of gonadotrophins and AMH), but who are not in a 
relationship will necessarily be concerned about the possibility or early menopause.  An 
increasing number are likely to turn to ovarian crypreservation techniques, subject to financial 
constraints and local availability 67.  Long-term outcome data for this in terms of live births will 
obviously take many years to accumulate.  
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Meanwhile, we have illustrated how recent scientific advances should already be altering 
clinician perceptions.  We have also sought to support clinicians managing uncertainties in the 
evidence base, with reference both to physiologic first principles and to informative data arising 
from other relevant patient groups.  Finally, we would emphasise that men and women 
presenting in advanced adult life with absent puberty cannot simply be “shoe-horned” into 
paediatric treatment algorhythms.   
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Tables  
Table 1:  Common Causes of Delayed Puberty other than Constitutional Delay of Growth and Puberty 
 Hypergonadotropic 
Hypogonadism 
Hypogonadotropic Hypogonadism Functional Hypogonadotropic 
Hypogonadism 
Common Causes: Turner Syndrome 
Gonadal Dysgenesis 
Chemotherapy/Radiation 
Therapy 
 
CNS Tumors/Infiltrative Diseases 
Isolated Hypogonadotropic 
         Hypogonadism 
Kallmann syndrome 
Combined Pituitary Hormone 
         Deficiency 
Chemotherapy/Radiation Therapy 
 
Systemic Illness/Conditions 
Inflammatory Bowel Disease 
Celiac Disease 
Anorexia Nervosa/Bulimia 
Hypothyroidism 
Excessive Exercise 
 
Table modified and reprinted with permission from Palmert MR, Dunkel L. Clinical practice. Delayed puberty. N Engl J Med 
2012;366:443-53. 6 
  
Table 2. Medications Used for the Treatment of Constitutional Delay of Growth and Puberty and Permanent Hypogonadism 
Drug and Formulation Induction of Puberty in  Boys 
 
Side Effects and Cautions 
 CDGP Hypogonadism  
Testosterone (T) *   Erythrocytosis, weight gain, 
prostate hyperplasia. High doses 
can cause premature epiphyseal 
closure. Not for use in boys with  
bone age < 10 yrs.  
T enanthate, cypionate, and 
propionate. T enanthate has 
longer duration of effect 
than T propionate. IM 
injection.  
Not recommended before 14 
yrs of age. Initial dose 50-100 
mg every 4 weeks for 3 to 6 
months. Repeated treatment 
with 25-50 mg increment in 
dose (not exceeding 100 mg)  
Can initiate after age 12 yrs at 50 
mg/month. Increase with 50 mg 
increments every 6 to 12 months. 
After reaching 100-150 mg monthly, 
decrease interval to every 2 weeks.  
Adult dose 200 mg every 2 weeks. 
All IM preparations: local side 
effects (pain, erythema, 
inflammatory reaction and sterile 
abscess). Priapism can occur in 
patients with sickle cell disease. 
 25 
T undecanoate 
IM injection  
No data available. Adult dose is 1000 mg every 10-14 
weeks. 
Very rarely, paroxysms of coughing 
and dyspnoea post-injection, 
ascribed to lipid embolism from the 
vehicle; hence not licensed in USA. 
T gel. Transdermal 
preparations, applied 
topically at bedtime.  
No data available. Can be started when approximately 
50% adult dose with IM T has been 
achieved. Adult dose 50-80 mg 
daily. 
Local irritation. After applying, 
avoid close skin contact with others  
Aromatase inhibitors**   Not yet approved for this indication.  
After onset of puberty,  may 
increase gonadotrophin secretion 
and circulating T levels 68.  
Letrozole PO  2.5 mg daily Not recommended Decreased HDL cholesterol, 
erythrocytosis, vertebral 
deformities have been reported 48.  
Anastozole PO  1.0 mg daily Not recommended Less potent than letrozole.  
 
Treatment of Fertility in Boys and Men 
 
 CDGP Hypogonadism  
Pulsatile GnRH 
s.c. pump 
Not recommended routinely Initial: 5-25 ng/kg/pulse every 90-
120 min; increase to 25-600 
ng/kg/pulse  
Requires extensive experience. Most 
physiological form of replacement. 
hCG plus recombinantFSH. 
SC or IM hCG  injections 
SC rhFSH injections 
Not recommended routinely hCG: Dose 500 to 3000IU twice 
weekly, increased to every 2 days. 
Dose adjusted based on serum T 
levels.  rhFSH: Dose 75to 225 IU 2-3 
times weekly.  
hCG: Inflammation locally in the 
testis, may induce apoptosis of germ 
cells. In hypogonadotropic 
hypogonadism with prepubertal 
onset it is necessary to add FSH to 
induce testicular growth and 
spermatogenesis. No data on effects 
on future fertility.  
Drug and Formulation Induction of Puberty 
In Girls 
 
Side Effects and Cautions 
 CDGP  Hypogonadism  
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Estrogen    
Ethinyl oestradiol (EE). 
Component of contraceptive 
pills. Lower dose EE PO 
preparations are available in 
Europe. 
Initial dose 2 mcg daily. 
Increase after 6-12 months 
to 5 mcg daily. 
Initial dose 2 mcg daily. Increase 
every 6 to 12 months to 5 mcg, 10 
mcg and 20 mcg daily (adult dose). 
Liver toxicity, increased levels of 
some plasma binding proteins. 
Potentially greater risk of 
thromboembolism and arterial 
hypertension than natural 
estrogens17β-oestradiol.  
17β-oestradiol.  
PO tablets 
 
Initial dose 5 mcg/kg daily 
PO, increase after 6-12 
months to 10 mcg/kg daily 
 
Initial dose 5 mcg/kg daily PO, 
increase every 6-12 months to10 
mcg/kg daily, then to 15 mcg/kg and 
to 20mcg/kg daily. Adult dose 1-2 mg 
daily.  
Natural estrogen, may be preferable 
to synthetic estrogens. Transdermal 
route may have advantages over 
oral administration.  
17β-oestradiol.  
Transdermal patch or gel.  
Patches twice weekly, 
topical gel applied daily. 
Patch: initial 3.1-6.2 
mcg/24h (1/8-1/4 of 25 
mcg/24h patch). Increase 
by 3.1-6.2 mcg/24h every 6 
months.  
Patch: initial 3.1-6.2 mcg/24h(1/8-
1/4 of 25 mcg/24h patch). Increase 
by 3.1-6.2 mcg/24h every 6 months. 
Adult dose 50 (to 100) mcg/24h.  
No dosage equivalent data between 
patches and gel available in younger 
patients. 
Conjugated equine 
estrogens (CEE) 
PO tablets. 
Initial dose 0.1625 mg daily 
for 6-12 months, and then 
titrating to 0.325 mg daily. 
Dosing depends on 
formulation. 
Initial dose 0.1625 mg for 6-12 
months, increase every 6-12 months 
to 0.325, 0.45, and 0.625 mg daily.  
Common adult dose 0.625 mg. 
CEE are not estradiol precursors.  
Use questioned by some as not 
physiological and because of 
reported increased cardiovascular 
risks in postmenopausal women.  
Progestogens/Progestins 
Various options, usually PO  
Usually necessary only if 
treatment continues longer 
than 12 months.  
5-10 mg of medroxyprogesterone 
acetate (MPA) daily during the last 7 
days of menstrual cycle. Alternative: 
micronized progesterone, dose 100-
200 mcg daily.   
Progesterone added to induce 
endometrial cycling after 12-18 
months of estrogen therapy (later if 
estrogen dose increased slowly; 
sooner if break-through bleeding).  
 
Treatment of Fertility in Girls and Women 
 
 CDGP Hypogonadism  
Pulsatile GnRH Not recommended 
routinely 
Used for fertility, as in male patients See considerations above 
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*Testosterone undecanoate PO tablets or anabolic steroids are not recommended for the induction of secondary sexual 
characteristics. 
Induction of fertility may be less successful in men who have lower baseline testicular volumes, have received previously 
testosterone treatment, and have not previously received treatment with GnRH 56-59 or gonadotrophins. 
**Rationale for the use of aromatase inhibitors in the induction of puberty in CDGP is to increase adult height. 
 
Table modified and reprinted with permission from Palmert MR, Dunkel L. Clinical practice. Delayed puberty. N Engl J Med 
2012;366:443-53. 6 
 
 
                                                          
 
 
